These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37279408)

  • 21. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
    Al-Sawaf O; Zhang C; Lu T; Liao MZ; Panchal A; Robrecht S; Ching T; Tandon M; Fink AM; Tausch E; Schneider C; Ritgen M; Böttcher S; Kreuzer KA; Chyla B; Miles D; Wendtner CM; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
    J Clin Oncol; 2021 Dec; 39(36):4049-4060. PubMed ID: 34709929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
    Fürstenau M; Giza A; Weiss J; Kleinert F; Robrecht S; Franzen F; Stumpf J; Langerbeins P; Al-Sawaf O; Simon F; Fink AM; Schneider C; Tausch E; Schetelig J; Dreger P; Böttcher S; Fischer K; Kreuzer KA; Ritgen M; Schilhabel A; Brüggemann M; Stilgenbauer S; Eichhorst B; Hallek M; Cramer P
    Blood; 2024 Jul; 144(3):272-282. PubMed ID: 38620072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
    Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
    Munir T; Cairns DA; Bloor A; Allsup D; Cwynarski K; Pettitt A; Paneesha S; Fox CP; Eyre TA; Forconi F; Elmusharaf N; Kennedy B; Gribben J; Pemberton N; Sheehy O; Preston G; Schuh A; Walewska R; Duley L; Howard D; Hockaday A; Jackson S; Greatorex N; Girvan S; Bell S; Brown JM; Webster N; Dalal S; de Tute R; Rawstron A; Patten PEM; Hillmen P;
    N Engl J Med; 2024 Jan; 390(4):326-337. PubMed ID: 38078508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
    Mauro FR; Starza ID; Messina M; Reda G; Trentin L; Coscia M; Sportoletti P; Orsucci L; Arena V; Casaluci GM; Marasca R; Murru R; Laurenti L; Ilariucci F; Stelitano C; Mannina D; Massaia M; Rigolin GM; Scarfò L; Marchetti M; Levato L; Tani M; Arcari A; Musuraca G; Deodato M; Galieni P; Patrizi VB; Gottardi D; Liberati AM; Giordano A; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; De Propris MS; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R
    Haematologica; 2023 Aug; 108(8):2091-2100. PubMed ID: 36632738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
    Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
    Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
    Thompson PA; Keating MJ; Ferrajoli A; Jain N; Peterson CB; Garg N; Wang SA; Jorgensen JL; Kadia TM; Bose P; Pemmaraju N; Short NJ; Wierda WG
    Leukemia; 2023 Jul; 37(7):1444-1453. PubMed ID: 37138019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.
    Lew TE; Anderson MA; Lin VS; Handunnetti SM; Came NA; Blombery P; Westerman DA; Wall M; Tam CS; Roberts AW; Seymour JF
    Blood Adv; 2020 Jan; 4(1):165-173. PubMed ID: 31935286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
    Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
    Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Cramer P; Tausch E; von Tresckow J; Giza A; Robrecht S; Schneider C; Fürstenau M; Langerbeins P; Al-Sawaf O; Pelzer BW; Fink AM; Fischer K; Wendtner CM; Eichhorst B; Kneba M; Stilgenbauer S; Hallek M
    Blood; 2021 Nov; 138(19):1805-1816. PubMed ID: 34086865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
    Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
    Herishanu Y; Shaulov A; Fineman R; Bašić-Kinda S; Aviv A; Wasik-Szczepanek E; Jaksic O; Zdrenghea M; Greenbaum U; Mandac I; Simkovic M; Morawska M; Benjamini O; Spacek M; Nemets A; Bairey O; Trentin L; Ruchlemer R; Laurenti L; Stanca Ciocan O; Doubek M; Shvidel L; Dali N; Mirás F; De Meûter A; Dimou M; Mauro FR; Coscia M; Bumbea H; Szász R; Tadmor T; Gutwein O; Gentile M; Scarfò L; Tedeschi A; Sportoletti P; Gimeno Vázquez E; Marquet J; Assouline S; Papaioannou M; Braester A; Levato L; Gregor M; Rigolin GM; Loscertales J; Medina Perez A; Nijziel MR; Popov VM; Collado R; Slavutsky I; Itchaki G; Ringelstein S; Goldschmidt N; Perry C; Levi S; Polliack A; Ghia P
    Am J Hematol; 2020 Jun; 95(6):604-611. PubMed ID: 32096887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
    Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
    Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Novak J; Strugov V; Gill D; Gribben JG; Kwei K; Dai S; Hsu E; Dean JP; Flinn IW
    Haematologica; 2022 Sep; 107(9):2108-2120. PubMed ID: 35021599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
    Kersting S; Dubois J; Nasserinejad K; Dobber JA; Mellink C; van der Kevie-Kersemaekers AF; Evers LM; de Boer F; Koene HR; Schreurs J; van der Klift M; Velders GA; van der Spek E; van der Straaten HM; Hoogendoorn M; van Gelder M; Posthuma EFM; Visser HPJ; Houtenbos I; Idink CAM; Issa DE; Dompeling EC; van Zaanen HCT; Veelken H; Levenga H; Tick LW; Terpstra WE; Tonino SH; Boyer M; Mobasher M; Levin MD; Kater AP;
    Lancet Haematol; 2022 Mar; 9(3):e190-e199. PubMed ID: 35240075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
    Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
    Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
    N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.